The in vitro and in vivo anti-tumor efficacy of methotrexate-loaded Fe 3 O 4 -poly-L-lactide-poly(ethylene glycol)-poly-L-lactide magnetic composite microspheres (MTX-Fe 3 O 4 -PLLA-PEG-PLLA MCMs, MMCMs), which were produced by co-precipitation (C) and microencapsulation (M) in a supercritical process, was evaluated at various levels: cellular, molecular, and integrated. The results at the cellular level indicate that MMCMs (M) show a better anti-proliferation activity than raw MTX and could induce morphological changes of cells undergoing apoptosis. At the molecular level, MMCMs (M) lead to a significantly higher relative mRNA expression of bax/bcl-2 and caspase-3 than MMCMs (C) at 10 µg mL 1 (P<0.01); and the pro-caspase-3 protein expression measured by Western blot analysis also demonstrates that MMCMs (M) can effectively activate pro-caspase-3. At the integrated level, mice bearing a sarcoma-180 tumor are used; in vivo anti-tumor activity tests reveal that MMCMs (M) with magnetic induction display a much higher tumor suppression rate and lower toxicity than raw MTX. Pharmacokinetic studies show that MMCMs (M) with magnetic induction significantly increase the accumulation of MTX in the tumor tissue compared with the other treatments. These results suggest that the MMCMs (M) prepared by the SpEDS process have great potential to play a positive role in the magnetic targeted therapy field. 
promising way to achieve a targeted delivery by some stimulus, such as temperature [12] , pH [13] , magnetic field [14] , or mutual combination [15, 16] . Among them, magnetic TDDS is used extensively to improve the targeting property by application of an external magnetic field; consequently, the therapeutic effects of drugs can be enhanced.
As a new drug formulation candidate for biomedical applications, its safety and effectiveness must be evaluated before entering the clinical trials stage because of the potential alteration in the biological effects of the drug to be transported. Traditionally, the evaluation of the effectiveness of a drug formulation has been focused on cell viability [17] . However, the evaluation at a cellular level is not comprehensive. For the sake of harvesting more reliable results, evaluating the effectiveness of the formulations at omnidirectional levels is necessary [18, 19] . At a cellular level, evaluation has mainly involved the detection of cell apoptosis by various methods with integrated advantages [20, 21] . At a molecular level, the expressions of the apoptosis-related genes and proteins [22, 23] have been the main focus of investigation. Evaluation at an integrated level has mainly examined anti-tumor activity and pharmacokinetics [24, 25] . With the rapid development of life science and special features of formulations, some of the new evaluation methods should be adopted [26] .
In our previous studies [27, 28] , using a process of SpEDS, MTX-Fe 3 O 4 -PLLA-PEG-PLLA magnetic composite microspheres were produced by co-precipitation and microencapsulation processes [MMCMs (C/M)], and the biocompatibility of Fe 3 O 4 -PLLA-PEG-PLLA MCMs was evaluated. In this work, based on the above results, the effectiveness of MMCMs (C/M) was evaluated at three levels: cellular, molecular, and integrated.
Materials and methods

Materials and cell culture
A schematic diagram of the SpEDS apparatus and the preparation process was shown in our previous study [27] . In this work, theoretical drug loads were set at 10%, and the corresponding drug loads of MMCMs (C) and MMCMs (M) were 11.72%±0.00% and 5.06%±0.01%, respectively. These microspheres were further treated through cobalt-60 radiation sterilization.
Alamar blue was purchased from Invitrogen (USA). A normal/apoptotic/necrotic cell detection kit and a BCA protein estimation kit were purchased from Kaiji Bio-Company (Nanjing, China). A cell cycle and apoptosis analysis kit, cell lysis buffer for Western blot analysis and immunoprecipitation (IP), phenylmethylsulfonyl fluoride (PMSF), and BeyoECL Plus were purchased from the Beyotime Institute of Biotechnology (Jiangsu, China). The RNAiso Plus, Prime Script TM RT reagent kit and SYBR Premix Ex Taq TM II (Tli RNaseH Plus) were purchased from TaKaRa Bio Ltd. (Dalian, China). All other chemicals were of analytical grade.
MG-63 cells (a human osteosarcoma cell line) and S-180 cells (a mouse sarcoma cell line) were purchased from the Committee of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). MG-63 cells were cultured in Dulbecco's Minimum Essential Medium (DMEM, Gibco, USA) and S-180 cells were grown in RPMI1640 Medium (Gibco, USA) supplemented with 10% heat-inactivated fetal bovine serum (Gibco, USA) and 1% antibiotics (100 U mL 1 penicillin and 0.1 mg mL 1 streptomycin) (Hyclone, USA). The cells were cultured in a humidified incubator at 37°C (95% humidity, 5% CO 2 ). Kunming mice were purchased from the Slac Laboratory Animal Co. Ltd. (Shanghai, China). Animals were kept in a facility and had free access to food and water, under a 12 h light/dark cycle.
Cellular level evaluation
In vitro anti-tumor assay
The anti-tumor activity of MMCMs against MG-63 cells was examined by a cell viability test using the Alamar blue proliferation kit. 100 µL of cell suspension was seeded in 96-well plates (Corning, USA) at a density of 3000 cells/well and incubated for 24 h to allow cell attachment. The culture medium was then replaced by 200 µL of MTX, MTX nanoparticles, or MMCMs (C/M) suspension (dispersed in DMEM with MTX concentrations of 0.01, 0.1, 1, 10, and 100 µg mL 1 ) for 72 h. In addition, a timedependent manner survey was performed: cells were incubated with 200 µL of MTX, MTX nanoparticles, MMCMs (C/M) (MTX concentrations of 3 µg mL
1
) or MCMs suspension (blank microspheres, polymer concentration of 100 µg mL 1 ) for 24, 48, 72, 120, and 168 h. Controls were cultivated under the same conditions with fresh medium. In order to negate the effects of medium evaporation, only the internal 60 wells were employed for testing and the outer wells had 200 µL of PBS added to them. At the determined time, assays were implemented according to the manufacturer's instructions. Briefly, the control and test samples were removed, and the cells were rinsed twice with PBS, then 100 µL of 10% (v/v) Alamar blue solution was added to each well. After incubation for 4 h, Alamar blue fluorescence was determined at 570 nm, using 600 nm as a reference wavelength by a microplate reader (Spectra Max M5, Molecular Devices, USA). The spectrophotometer was calibrated to zero absorbance using culture medium without cells (blank). Cell viability and half inhibitory concentration (IC 50 , modified Kou-type method) were calculated with the following formula:
Cell viability (%)=[A 570600 (sample)A 570600 (blank)]/ [A 570600 (control)A 570600 (blank)], lgIC 50 =XmI(P(3PmPn)/4).
Here, Xm is lg(maximum dose); I is lg(maximum dose/adjacent dose); P represents sum of positive response rate; Pm represents the largest positive response rate; Pn represents the smallest positive response rate; positive response rate=1−cell viability. Data were presented as mean± standard deviation (SD) with 6-well repeats.
Morphological observation
The morphologies of apoptotic and necrotic cells were detected by AO-EB fluorescence staining. Exponentialgrowth-phase MG-63 cells were seeded at a final concentration of 1×10 5 /well in 24-well plates and cultured for 24 h, after which the culture medium was removed and 1 mL of the test sample solutions was added. After 48 h of incubation, according to the instructions of the normal/apoptotic/ necrotic cell detection kit, the cells were harvested with 0.25% trypsin and re-suspended in 1 mL of DMEM medium. After the cells were washed twice with PBS and re-suspended in 100 µL of PBS, 25 μL of the cell suspension was mixed with 1 μL of a mixed dyes reagent for 23 min in darkness, then 10 µL of samples was placed on a microscope slide and visualized under a fluorescence microscope (Leica, German) using a blue filter.
Cell cycle assay
The cell cycles were determined by flow cytometry with PI staining according to the cell cycle and apoptosis analysis kit. A total of 8×10 5 MG-63 cells were seeded in 6-well plates; after being subcultured for 24 h, the medium was changed to an incomplete medium for 12 h for cell cycle synchronization, and then the cells were treated with 2 mL of the test sample solutions for 48 h. Three dishes with different concentrations were prepared, and then the adhesive cells and suspended cells were harvested, pooled, and pelleted. After being washed twice with PBS, the cells were fixed in ice-cold 70% (v/v) ethanol for 24 h at 4°C. Before analysis, the cells were washed with 1 mL of PBS and filtered through a 200 mesh sieve, centrifuged, suspended in 0.5 mL of staining buffer containing RNase A and PI, and then incubated at 37°C for 30 min in darkness. The cells were analyzed with a fluorescence excitation wavelength of 480 nm using a Cell Lab Quanta SC flow cytometer (Beckman Coulter).
Molecular level evaluation
Real-time reverse transcription polymerase chain reaction (real-time RT-PCR) assay
The mRNA expressions of bcl-2, bax, and caspase-3 genes were detected by real-time RT-PCR. After 1×10 6 MG-63 cells were seeded in 6-well plates and incubated for 24 h at 37°C, the test sample solutions were added to each group, with a further incubation for 72 h. The intracellular total RNA was extracted with Trizol reagent, and the purity and concentration were measured by ultraviolet spectrophotometry; the quality was checked by agarose gel electrophoresis. The Prime Script ® RT reagent Kit was then used to construct the cDNA library, which was further accessed as the template of the real-time PCR. The specific primer and β-actin (internal control) sequences (Shanghai Sangone Company, China) are listed in method [29] .
Western blot assay
The expression of pro-caspase-3 protein in MG-63 cells was detected by Western blot analysis. The cells were first treated according to the same procedure described for the real time RT-PCR assay, and then the cell lysates were prepared following harvesting of the cells in cell lysis buffer for Western blot analysis and IP. The protein was quantified by a BCA protein estimation kit, and 100 µg of proteins per lane was separated by 12% sodium dodecyl sulfate poly- with TBST buffer containing appropriate amounts of primary antibodies: caspase-3 (1:400; Boster, China) and β-actin (1:3000; Bioworld Technology, USA). The blots were then washed three times with TBST and incubated with anti-rabbit secondary antibody conjugated with horseradish peroxidase (HRP) (1:1000; Beyotime, China). The membranes were washed three times again, and the protein signals were detected by an ECL plus kit using an image analyzer (Kodak Image Station 4000 MM Pro). Densitometric analysis was performed using the Quantity One software version 4.6.2.
Integrated level evaluation
In vivo anti-tumor activity
In vivo anticancer activity against sarcoma-180 (S-180) solid tumors was evaluated in KM mice. Viable S-180 tumor cells ((13) ×l0 6 ) were propagated in the intraperitoneal cavity of adult KM mice by intraperitoneal injection. The S-180 ascites tumor cells were then harvested on the eighth day and suspended at (12)×10 7 cells mL 1 in strokephysiological saline solution; 0.2 mL of this cell suspension was inoculated subcutaneously into the right armpit of the mice using a 1.0 mL syringe. When the tumor volumes reached about 300 mm 3 (about six days after tumor inoculation), the mice were randomly divided into seven groups (six mice/group). Groups 1, 2, and 3 were injected with PBS (control), MCMs, and MTX, respectively. Groups 45 and 67 were treated with MMCMs (C) and MMCMs (M), respectively. For groups 5 and 7, the tumors were exposed to a 0.4 T magnetic field produced by a permanent magnet with the help of adhesive tapes immediately after administration [30] . The dose of MTX was 10 mg kg 1 drug equivalent in all experimental mice. Each test compound was administered via tail vein injection every other day for 10 d (five times). Body weight and tumor volume were measured at defined drug administration periods, and tumor volume was calculated based on the following equation: major axis×(minor axis) 2 ×1/2. Twenty-four hours after the last administration, the animals were sacrificed by cervical dislocation, and the tumor mass was harvested and weighed. The inhibitory rate of the tumor was calculated by the following formula:
where A is the average tumor weight of the negative control and B is that of the treated group. At the end of the experiment, the tumor and small intestine tissues were fixed with 10% formaldehyde for 24 h and embedded in paraffin. Each section was cut to 5 µm, processed for routine hematoxylin and eosin (H&E) and Prussian blue staining, and photographed under an Olympus microscope (BX-51).
Pharmacokinetics assay
Pharmacokinetics studies were performed using S-180-bearing KM mice models. In total, 84 mice were randomly assigned to three groups (28 mice per group): MTX solution, MMCMs (M), and MMCMs (M) (with magnetic induction). The mice were treated with a single tail vein injection at an MTX dose of 10 mg kg 1 for each mouse. For the pharmacokinetic experiment, at the designated times (5, 15, and 30 min and 1, 2, 4 and 12 h) after administration, blood samples were taken from the retro orbital plexus, and plasma was isolated by centrifugation (10 min at 3000 r min 1 ) and stored at 20°C. The mice were then sacrificed and the major tissues, including the tumor and the liver, were collected, washed with saline, blotted dry with filter paper, wrapped with tinfoil, and stored at 80°C for assay. For the plasma sample preparation, 200 µL of the plasma sample was added to 100 µL of saline and 100 µL of perchloric acid (20%). For the tissue sample preparation, 300 µL of tissue homogenate was added to 300 µL of perchloric acid. The sample mixture was thoroughly vortex-mixed for 5 min, followed by centrifugation at 10000 r min 1 for 10 min. The supernatant was then centrifuged again, filtered through a 0.22 µm filter membrane, and transferred to a fresh tube. 20 µL of this solution was injected into the high performance liquid chromatography (HPLC) (LC-2000, Japan) system for analysis, with experimental conditions as follows: C18 column (150 mm×4.6 mm, pore size 5 µm); the mobile phase, 3% glacial acetic acid: acetonitrile (90:10, v/v); flow rate, 1.0 mL min 1 ; column temperature, 35°C; measured wavelength, 303 nm. Non-compartmental pharmacokinetic analysis was performed using the software Winnonlin. The animal experiments were carried out in accordance with the guidelines issued by the Ethical Committee of Huaqiao University.
Statistical analysis
Data were expressed as mean±SD. Results were analyzed by one-way ANOVA. P<0.05 was considered statistically significant and P<0.01 was considered highly statistically significant.
Results and discussion
The effect of MMCMs (C/M) on MG-63 cell growth in vitro
Prior to in vivo evaluation, the anti-tumor activity of the Figure 1 , the cell viability of MG-63 cells incubated with MCMs was close to 100% during the experimental period. It was observed that exposure of MG-63 cells to MTX nanoparticles significantly decreased cell viability after four days in comparison with exposure to raw MTX over the same period (P<0.01).
In comparison with the response to raw MTX, the cell viability with MMCMs (C/M) kept decreasing after three days (P<0.01); furthermore, values for cell viability with MMCMs (M) were the lowest on the seventh day (P<0.01).
The results indicate that MCMs had almost no effect on cell proliferation, and this was consistent with a previous report [32] . MTX nanoparticles could induce a lower cell viability than raw MTX, which could be explained by the fact that a significant increase in the dissolution rate of MTX nanoparticles occurred to increase the bioavailability of MTX [33] . proliferation activity than the other formulations. However, the cell viability in the MMCMs (M) group was not significantly decreased when compared with previous reports [34, 35] . This can be explained that the concentration of MTX (3 µg mL 1 ) was chosen according to achievable plasma drug levels in humans, and it was lower than the level of IC 50 . We believe that the cell viability will be significantly decreased when the concentration of MTX is increased with the increasing in drug load of MMCMs (M).
The effect of MMCMs (C/M) on MG-63 cell morphology
AO-EB dual staining is commonly used to study the death pattern of cells, distinguishing the viable cells, early/ medium/late apoptotic cells, and necrotic cells [36] . It is known that AO is a cell-permeable dye that intercalates into DNA and emits green fluorescence, while EB enters cells with disrupted membrane integrity and intercalates into RNA and DNA, appearing orange in color. As shown in Figure 2 , after AO-EB staining, the control cells (A) and cells treated with MCMs (B) emitted uniformly green fluorescence and almost no death or apoptosis was observed. In contrast, the cells treated with MTX (C) showed the presence of non-uniform green patches of fragmented and condensed chromatin, which are the characteristics of early apoptosis. However, some of the cells incubated with the MTX nanoparticles (D) and MMCMs (C/M) (E/F) exhibited obvious orange patches of fragmented and condensed chromatin, nuclear fragmentation, or apoptotic bodies, all of which are characteristics of apoptotic programmed cell death. Therefore, the above observations demonstrated that MMCMs (C/M) could dramatically induce apoptosis of MG-63 cells [37] , which was also supported by the results obtained from the effect of MMCMs (C/M) on MG-63 cell growth in vitro.
The effect of MMCMs (C/M) on the MG-63 cell cycle
A quantitative evaluation of MMCMs-induced cell death was carried out through cell cycle analysis using PI staining, which was intended to reflect cell proliferation at various stages of cells. PI is a kind of double-stranded DNA fluorescent dye; their combination can produce fluorescence, which is detected by flow cytometry, and thus the DNA contents are calculated [38] . The effects of different kinds of MTX formulations on the cycle of MG-63 cells over 48 h are shown in Figure 3 , which shows an increase in the S phase compared with the control (P<0.01) and also a decrease in the G 0 /G 1 phase. It was observed that the S phase with 3 µg mL 1 of MMCMs (C/M) increased up to 46.83% and 48.18%, respectively, while 5.91% in the control. At the same time, the G 0 /G 1 phase decreased from 78.29% in the control to 36.36% and 34.62%, respectively. There were no significant statistical differences (P>0.05) between the effects of MTX and MMCMs (C/M) in the S phase, which indicated that MMCMs (C/M) did not decrease efficacy and arrest the cell cycle in the S phase. As demonstrated by other published data, MTX is an S phase specific drug, which generally produces growth arrest in the S phases of the cell cycle [39] .
The effect of MMCMs (C/M) on the expression of mRNA and protein levels
The ratio of the pro-apoptotic (bax) to anti-apoptotic (bcl-2) molecules is crucial in apoptosis [40] . Inhibition of the expression of bcl-2 will result in the activation of caspase-3, which is a key factor of the Caspase family and plays a very important role in cell apoptosis. Therefore, we studied the effect of MMCMs (C/M) on bcl-2, bax, and caspase-3 mRNA and pro-caspase-3 protein expression. The results of real-time RT-PCR are shown in Figure 4A and B. The relative expression levels of bax/bcl-2 and caspase-3 mRNA in MTX were higher than those of the other treatments. The expression levels of MMCMs (M) were much higher than those of MMCMs (C), and the difference was statistically significant (P<0.01). The changes in the transcriptional profiles of the caspase-3 gene were further reconfirmed by Western blot analysis. Potent apoptosis markers such as pro-caspase-3 protein were all found to be significantly decreased in response to the test chemicals [41] . As shown in Figure 5A and B, the pro-caspase-3 protein in the 10 µg mL 1 of MMCMs (M) was the lowest among all of the for-
mulations. These results demonstrate that MMCMs (M) had a pro-apoptotic effect on MG-63 cells, which could effectively increase the gene expression of bax/bcl-2 and caspase-3 and activate the protein expression of pro-caspase-3 more effectively than MMCMs (C).
The effect of MMCMs (C/M) on tumor growth in vivo
To investigate the anti-tumor efficacy of MMCMs (C/M) in vivo, we here selected S-180 tumor-bearing mice as an animal model because it has been one of the classical solid tumor models for a long time [42] . Tumor volumes, weights, and inhibitory rates were used as evaluating indicators of efficacy and are shown in Figure 6 and Table 2 . Relative to PBS, MCMs resulted in a similar increase in tumor volume at all-time points after treatment, with a relatively low IR (10%) (P>0.05). However, the other groups showed a tumor growth suppression activity. When the mice were treated with MTX alone, a mean tumor volume of 1260±180 mm 3 after the last dosing (P<0.01) and a relatively high IR (49%) were observed. Under a magnetic field of 0.4 T, MMCMs (C) and MMCMs (M) showed mean tumor volumes of 800±170 (P<0.05) and 560±40 mm 3 (P<0.01) after the last dosing, respectively, as well as a high IR (54% and 64%, respectively). Furthermore, the difference between the effects of MMCMs (C) and MTX after the last dosing was significant (P<0.05), and the difference between the effects of MMCMs (M) and MTX (P<0.01) after the last dosing was highly significant. This clearly indicates that MMCMs (M) under magnetic induction could significantly improve the anti-tumor activity of MTX.
The representative microphotographs of H&E-stained sections of S-180 tumor cells are shown in Figure 7 . Figure  7A reveals the presence of typical tumor cells with good growth in the S-180 control group (PBS), where the nuclei were dyed bright blue by hematoxylin, the cytoplasm was dyed in different shades of pink by eosin, and tumor cells were dense. However, when the mice were treated with MTX and MMCMs (C) subjected to magnetic induction, large pink areas and intercellular space can be seen, indicating necrosis ( Figure 7B and C) [43] . Furthermore, MMCMs (M) under magnetic induction showed more extensive necrotic areas than the other formulations ( Figure  7D ). This was consistent with the results of inhibitory rates. Meanwhile, tumor tissues were also observed by Prussian blue staining ( Figure S2 in Supporting Information). There were no blue iron particles in the PBS and MTX groups. The MMCMs (C) group showed only small amounts of blue iron particles under magnetic induction, while the MMCMs (M) group showed a lot of blue iron particles under magnetic induction. The above observations also proved that MMCMs (M) could considerably improve anti-tumor activity under magnetic induction. The major limitation of cancer chemotherapy is the injury of normal tissue, leading to multiple organ toxicity. MTX is a frequently used cytotoxic agent in the clinic and is associated with acute and chronic neurotoxicity [44] . In order to determine whether MMCMs (C/M) may cause any undesirable side-effects, we assayed the change in body weight [45] and H&E staining of normal tissue (small intestine) [46] as indicators of general toxicity. As presented in Figure 8 , relative to PBS injected animals, MTX caused a significant weight loss by day 7 (P<0.05). Obviously, MMCMs (C) with magnetic induction resulted in a highly significant weight loss after 7 d (P<0.01). In contrast, the MMCMs (M) group under magnetic induction showed a similar increase in mean mice weight at all-time points after treatment (P>0.05), suggesting that MMCMs (M) were better tolerated than others. Subsequently, as shown in Figure 9 , compared with the control, severe toxicity induced by raw MTX was found, such as inflammation. The findings indicated that MMCMs (M) were associated with fewer harmful side-effects of MTX than MMCMs (C) under magnetic induction. Thus, compared with raw MTX and MMCMs (C), MMCMs (M) were demonstrated to be more curative and less toxic to the mice. 
Pharmacokinetics study
To further confirm the above results, the pharmacokinetic behavior of MMCMs (M) was assessed in S-180 tumor-bearing mice. After intravenous administration of MTX solution, MMCMs (C), and MMCMs (M) in the presence of a magnetic field, the concentrations of MTX in plasma, liver, and tumor were determined by HPLC. The concentration versus time profiles of these tissues are shown in Figure 10 . The corresponding pharmacokinetic parameters in plasma and tissues are listed in Table 3 . As shown in Figure 10 , the MTX concentration had a quick decrease after 15 min dosing in the plasma, liver, and tumor. MMCMs (M) under magnetic induction displayed a longer systemic circulation time, especially in the tumor, which suggested a greater in vivo targeted effect.
As shown in Table 3 , for the MTX solution treatment, the maximum concentrations (C max ) in the plasma, liver, and tumor were much higher than those of the other treatments. By application of the external magnetic field, in the MMCMs (M) group, the C max increased significantly from 721 to 979 ng mL 1 in the tumor. Furthermore, for time at [47] developed MTX-loaded thermosensitive magnetoliposomes, when these liposomes were intravenously administrated in rats, 3.85-fold increase of C max and 9.68-fold increase of MTX accumulation (AUC 0−t ) in skeletal muscle compared with the absence of magnet were observed. Similar phenomena were also found in our study, the pharmacokinetic behaviors of MTX had a marked difference among the free MTX solution, MMCMs (M) and MMCMs (M) in the presence of magnetic field. MMCMs (M) under magnetic induction increased C max in 1.36-fold and AUC 0−t in 2.78-fold compared with the absence of magnet, and 2.0-fold increase of T max and 2.13-fold increase of AUC 0−t compared with free MTX.
The increase in C max indicated that the nanoparticles were effective in increasing the drug absorption, and the delayed T max demonstrated an obvious sustained release of MTX. This was probably because that MMCMs (M) had a good magnetic response and sustained-release effect. Overall, under magnetic induction, MMCMs (M) showed the greatest accumulation of MTX in tumor tissues compared with the other formulations, resulting in an increase in the therapeutic index and safety profile of MTX.
Conclusion
To use the MMCMs (C/M) in a drug delivery system, we evaluated their biological effectiveness by measuring their in vitro and in vivo anti-tumor effects. The anti-tumor efficacy in MG-63 cells was enhanced by MMCMs (M), which have an effective long-term anti-tumor effect and induce cell cycle arrest in vitro. In addition, MMCMs (M) increased the gene expression of bax/bcl-2 and caspase-3 and activated the protein expression of pro-caspase-3 more effectively than MMCMs (C). Moreover, MMCMs (M) significantly decreased tumor growth and showed a lower toxicity in vivo. The pharmacokinetics study showed that the MTX C max , T max , t 1/2 , and AUC were significantly increased by MMCMs (M) under magnetic induction, while distribution and clearance were decreased, indicating a prolonged circulation time and an increased bioavailability. Based on our present data, MMCMs (M) show great potential for use in the magnetic targeted therapy field.
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